Emerging Role of microRNAs as Liquid Biopsy Biomarkers in Lung Cancer: A Review
,
Abstract
The emergence of patient-tailored medicine has changed all measurable disease outcomes. Among human diseases, cancers appear to be the most dangerous. Furthermore, lung cancers rank the first among human cancers in both morbidity and mortality. When lung cancer is clinically diagnosed, it is often too late for therapy. The absence of accurate and specific tools for early detection results in a poor prognosis for lung cancer. The discovery of microRNAs and their function in lung cancer offers a new mechanism for the detection of lung cancer cells. These molecules, derived from cancerous cells, circulate in the patient's blood. Recently, a revolutionary technique, i.e., liquid biopsy has shown promise in discovering these circulating microRNAs molecules in body fluids, namely peripheral blood. A liquid biopsy allows the detection and isolation of circulating tumor cells, circulating nucleotides, and cellular exosome as a source of genomic and proteomic information in cancerous patients, especially in the early stages of cancer cell development. In this review, by searching various databases, including PubMed, Google Scholar, and Scopus, we explore liquid biopsy as a novel tool and the application of miRNAs in lung cancer detection in diagnostic pathology.
1. Chakaravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alteration in cancer. Am J Pathol 2016; 187:1724-35.
2. Mattoox AK, Bettegowde C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Application of liquid biopsy for cancer. Sci transl Med 2019:11.eaay1984.
3. Siegle RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69:7-34.
4. Stewart BW, Wild CF. World Cancer report, 2014. International Agency for Research on Cancer (IARC). Lyon, 2014.
5. Bray F, Ferlay J, Saerjomataran I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer L Clin 2018; 68:394-424.
6. Heron M, Anderson RN. Changes in the leading cause of death; recent pattern in heart disease and cancer mortality. NCHS Data Brief 2016; 254:1-8.
7. Malvezzi M, Garioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality prediction for the year 2017 with focus on lung cancer. Ann Oncol 2017; 27:1117-23.
8. Schiffman JD, Fisher PG, Gibbs P. Early detection of cancer: past, present and future. Am Soc Clin Oncol Educ Book 2015; 35:57-65.
9. Saarenheimo J, Eigeliene N, Andersen H, Tiirola M, Jekunen A. The value of liquid biopsies for guiding therapy decision in non-small cell lung cancer. Front Oncol 2019; 9:129.
10. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553:446-54.
11. Trama A, Boffi R, Contiero P, Buzzoni C, Pacifici R, Mangone L, et al. Trends in lung cancer and smoking behavior in Italy: an alarm bell for women. Tumori 2017; 103:543-50.
12. Fortunato O, Gasparini P, Boeri M, Sozzi G. Exo-miRNAs as a new tool for liquid biopsy in lung cancer. Cancers (Basel) 2019; 11:888.
13. Lung cancer screening. CDC report. (Accessed June 13, 2021, at: hhtps://www.cdc.gov.cancer.lung.)
14. Dama E, Melocchi V, Colangelo T, Cuttano R, Bianchi F. Deciphering the molecular profile of lung cancer: New strategies for early detection and prognostic stratification. J Clin Med 2019; 8:108.
15. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J. Early and locally advanced NCSLC. ESMO clinical guideline for diagnosis/treatment and follow-up. Ann Oncol 2017; 28:iv1-21.
16. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 2018; 16:370-78.
17. Herceg Z, Halinaut P. Genetic and epigenetic alteration as biomarkers for cancer detection, diagnosis and prognosis. Med Oncol 2007; 1:26-41.
18. Ansari J. The liquid biopsy in lung cancer. Genes Cancer 2016; 7:355-69.
19. Nature news comments. Liquid-biopsies success highlights power of combining basic and clinical research. Nature 2017; 544:393.
20. Wu Z, Vang Z, Daei J, Zhu Q, Chen LA. Update on liquid biopsy in clinical management of NSCLC. Oncol Target Ther 2019; 12:5097-109.
21. Hofman P. liquid biopsy for early detection of lung cancer. Curr Opin Oncol 2017; 1:73-8.
22. Santarpia M, Liguori A, D’Aveni A, Karachaliou N, Gonzalez-Cao M, Grazia Daffinà M. Liquid biopsy for lung cancer early detection. J Thorac Dis 2018; 10:s882-97.
23. Best MG, Wesselling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res 2018; 78:3407-12.
24. Du X, Zhang J, Wang J, Lin X, Ding F. Role of microRNAs in lung cancer; potential biomarkers and therapies. Curr Pharm Des 2018; 23:3997-6010.
25. Su YH. Liquid biopsy: an old concept with a new twist. Genetic testing and molecular biomedicine, 2019. Seracare. (Accessed December 6, 2021, at https://www.genengnews.com/insight/liquid-biopsy-an-old-concept-with-a-new-twist/.)
26. Ashworth T. A case of cancer in which cells similar to those in the tumor were seen in blood after death. Med J Sust 1869; 14:146-7.
27. Follain G. Hemodynamic force tune the arrest, adhesion and extravastion of circulating tumor cell. Dev Cell 2018; 45:33-52.
28. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer genetic in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
29. Prakis S, Speicher MR. Merging in liquid biopsy. BMC Med 2017;15:79.
30. COBAS. COBAS EGFR Mutation Test v2. (Accessed at, https://www.cobaCF.com.)
31. University of Texas M D Anderson Cancer Center. Liquid as effective as tissue biopsy for NSCLC. Science Daily; February 27, 2019.
32. Bayes-ginis A, Nonez J. Step-by-step towards biomarker based precision medicine in heart failure. Clin Chem 2019;65:1187-9.
33. Lim M, Kim CJ, Sunkara V, Kim MH, Cho YK. Liquid biopsy in lung cancer: clinical application of circulating biomarkers (CTCs and ctDNA). Micromachines(Basel) 2018;9:100.
34. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018; 10:1758835918794630.
35. Sittka A, Schmeck B .MicroRNAs in the lung. Adv Exp Med Biol 2013:774; 121-34.
36. Sessa R, Hata A. Role of microRNAs in lung development and pulmonary diseases. Pulm Circ 2013; 3:315-28.
37. Muller S, Janke F, Dietz S, Sültmann H. Circulating microRNAs as potential biomarkers for lung cancer. Recent Results Cancer Res.2020; 215:299-318.
38. Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med 2015; 109:803-12.
39. Cruz-Miranda GM, Hidalgo-Miranda A, Bárcenas-López DA, Núñez-Enríquez JC, Ramírez-Bello J, Mejía-Aranguré JM, et al. Long non-coding RNA and acute leukemia. Int J Mol Sci 2019; 20:735.
40. Joosse SA, Gorges TM, Pantel K. Biology, detection and clinical implication of circulating tumor cells. EMBA Mol Med 2015; 7:1-11.
41. Kim WJ, Lim JH, Hong Y, Hong SH, Bang CY, Lee JS, et al. Altered miRNAs expression in lung tissue of patients with COPD. Mol cell toxicol 2017; 13:207-12.
42. Mondejer-Perreno G, Gallajo M, Cogolludo A, Pérez-Vizcaíno F. MicroRNAs in respiratory diseases. Nucleic acid nanotheranstics 2019;2:89-131.
43. Castro D, Moreiera M, Gouveia AM. Pozza DH, De Mello RA. MicroRna in lung cancer. Oncotarget 2017; 8:81679-85.
44. Padgin T, Lavander P. MicroRNAs in lung disease. Thorax 2012; 67:182-4.
45. Mitcheli PS, Parkin RK, Keroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood–based markers for cancer detection. Proc Nat Acad Sci USA 2008; 105:10513-8.
46. Lu J, Getz G, Miska EA, Lamb J, Peck D, Sweet-Cordero A, et al. MicroRNA genes expression profiles classify human cancer. Nature 2005; 435:834-8.
47. Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western population. Cancer Med 2018; 7:4849-62.
48. Lee RC, Feinbaum RL, Ambros V. The C-elegans heterchronic gene lin-4 encode small RNAs with antisense complementarity to lin-4. Cell 1993; 75:843-54.
49. Pasquinelli AE, Reinhart BJ, Slack F, Kuroda MI, Maller B, Hayward DC, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408:86-9.
50. Bahadori M. New advances in RNAs. Arch Iran Med 2008; 11:435-43.
51. Iorio MV, Croce CM. MicroRNAs in cancer. Small molecules with huge impact. J Clin Oncol 2009; 27:5848-56.
52. Bagheri A, Khorshid HRK, Tavallaei M, Mowla SJ, Sherafatian M, Rashidi M, et al. A panel of non-coding RNA in NSCLC. J Cell Biochem 2018 (Online ahead of print).
53. Gasparri ML Cosarelli A, Bardhi E, Raad Besharat A, Savone D, Ruscito I, et al. Beyond circulating microRNAs: urinary miRNAin ovarian and breast cancer. Tumori Biol 2017; 39:1010428317695525.
54. Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y, et al. The role of micro RNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int J Mol Sci 2017; 18:2540.
55. Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, et al. Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy:a prospect study. Clin Cancer Res 2019; 25:2166-73.
56. Mizuno k, Mataki H, Seki N, Kumamoto T, Kamikawaji K, Inoue H, et al. MicroRNAs in NSCLC and idiopathic pulmonary fibrosis. J Hum Genet 2017; 62:57-65.
57. Lu J, Zhan Y, Feng J, Luo J, Fan S. MicroRNAs associated with therapy of non-small cell lung cancer. Int J Buiol Sci 2018; 14:390-7.
58. Cui S, Cheng Z, Qin W, Jiang L. Exosome as a liquid biopsy for lung cancer. Lung Cancer 2018; 116:46-54.
59. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosome. Curr Opin Cell Biol 2014; 29:116-25.
60. Christianson HC, Svensson KJ, van Kuppevelt TH, Li JP, Belting M. Cancer cell exosome depend on cell surface heparin sulfate proteoglycans for their internalization and functional activity. Proc Nat Acad Sci USA. 2013; 110:17380-85.
61. Hoshino A, Costa Siva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumor exosome integrins determine organotropic metastasis. Nature 2015; 527:329-35.
62. Sanz-Rubio D, Martin-Burriel I, Gil A, Cubero P, Forner M, Khalyfa A, et al. Stability of circulating exosomal miRNAs in healthy subjects. Sci Rep 2018;8:10306.
63. Kim JH, Kim E, Lee MY. Exosome as diagnostic biomarkers in cancer. Mol Cell Toxicol 2018; 14:113-22.
64. Izzotti A, Carozzo S, Pulliero Q, Zhabayeva D, Ravetti JL, Bersimbaev R. Extracellular microRNA in liquid biopsy: applicability in cancer diagnosis and prevention. Am J Cancer Res 2016; 6:1461-93.
65. Chen X, Jin Y, Feng Y. Evaluation of plasma extracellular vesicle MicroRN signature for lung adenocarcinoma and granuloma with Monte Carlo feature selection method. Front Genet. 2019; 10:367.
66. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Respect Clin Res 2016; 7:68-74.
67. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell carcinoma using a novel microRNA – based approach. Clin Cancer Res 2010; 16:610-9.
68. Hamamoto J, Soeijima K, Yoda S, Naoki K, Nakayama S, Satomi R, et al. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep 2013; 8:456-62.
69. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, et al. Classification of the four main types of lung cancer using amicroRNA-based diagnostic assay. J Mol Diag 2012; 14:510-7.
70. Kim J, Lim NJ, Jang SG, Lee GK. MiR-592 and miR-552 can distinguish between primary lung adenocarcinoma andcolorectal cancer metastasis in the lung. Anticancer Res 2014; 34:2297-302.
71. Zaporozhchenko IA, Morozkin ES, Skvortsova TE, Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Plasma miR-196 and miR-183 is potential biomarkers of lung cancer. PLoS One 2016;11:e65261
72. Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating microRNA as noninvasive biomarkers for early detection of NSCLC. PLoS One 2015; 10:e0215026.
73. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC,et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations,copy number,chromosomal instability, and methylation. PLoS One 2012; 7:e36530.
74. Dama E, Melocchi V, Dezei F, Pirroni S, Carletti RM, Brambilla D, et al. An aggressive subtype of stage I lung adenocarcinoma with molecular and prognostic characteristics typical of advanced lung cancer. Clin Cancer Res 2017; 23:62-72.
75. de Bruin EC, Mc Granahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability process defines lung cancer evolution. Science 2014; 346:251-6.
76. Su JL, Chem PS, Johansson G, Kuo ML. Function and regulation of let-7 family microRNAs. Microma 20212; 1:34-9.
77. Roush S, Slack FJ. The let-7 family of miRNAs. Trends cell Biol 2008; 10:505-16.
78. Zhang J, Fujimoto J, Wedge DC, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lug adenocarcinoma delineated by multiregion sequences. Science 2014; 346:256-9.
79. Xiao W, Zhong Y, Wu L, Yang D, Ye S, Zhang M. Prognostic value of microRNAs in lung cancer: A systematic review and meta-analysis. Mol Clin Oncol 2019; 10:67-77.
80. Wikipedia. OncomiR. (Accessed at, https://en.wipedia.org>wiki>oncomir.)
81. Hamond SM. RNAi, microRNA and human disease. Cancer Chemother Pharmacol 2000;58:s63-8.
82. Calin GA, Du Mitro CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequentdeletin and down-regulation of microRNA genes miR-15 and mir-16 at 13q14 in chronic lymphocytic leukemia.Pro Nat Acad USA 2002;99:15524-9.
83. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29:618-26.
84. Yang M, Shen H, Qui C, Ni Y, Wang L, Dong W, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavorable survival in NSCLC. Eur J Cancer 2013; 49:604-15.
85. Si W, Shen JN, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics 2019; 11:25.
86. Frixa T, Donzelli S, Blanding G. Oncogenic MicroRNAs; key players in malignant transformation. Cancers (Basel) 2015; 7:2466-85.
87. Zhang C, Wang H, Liu X, Hu Y, Ding L, Zhang X, et al. Oncogenic microRNA-411 promote lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene 2018; 38:1892-909.
88. Pan X, Wang ZX, Wang R. MicroRNA-21, a novel therapeutic target in human cancer. Cancer Biol Ther 2010; 12:1224-32.
89. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu Q, et al.microRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 2013; 17; 1073-80.
90. Sachdeva M, Zhu S, Mo YY. MicroRNA-21 as a novel therapeutic target in cancer. Current Cancer Therapy 2010; 6:41-50.
91. Holohan C, Van schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistant: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26.
92. Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in NSCLC, a challenge landscape. Ann Oncol 2016; 27:2004-16.
93. Vargas AJ, Harris CC. Biomarker development in the precision medicine era. Lung Cancer as a case study. Nat Rev Cancer 2016; 16:325-37.
94. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision Medicine. Cancer Res 2019; 79:2798-804.
95. Saliminezad K, Khorshid HRK, Ghaffari SH. Why have microRNA biomarkers not been translated from bench to clinic.Future Oncol 2019;15.(Published Online)
96. Wholly D. The biomarkers consortium. Nat Rev Drug Discov 2014; 13:791-2.
97. Menetski J, Austin CP, Brady LS, Eakin G, Leptak C, Meltzer A, et al. The FINH biomarkers consortium embraces the BEST. Nat Rev Drug Discov 2019;18:567-8.
2. Mattoox AK, Bettegowde C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Application of liquid biopsy for cancer. Sci transl Med 2019:11.eaay1984.
3. Siegle RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69:7-34.
4. Stewart BW, Wild CF. World Cancer report, 2014. International Agency for Research on Cancer (IARC). Lyon, 2014.
5. Bray F, Ferlay J, Saerjomataran I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer L Clin 2018; 68:394-424.
6. Heron M, Anderson RN. Changes in the leading cause of death; recent pattern in heart disease and cancer mortality. NCHS Data Brief 2016; 254:1-8.
7. Malvezzi M, Garioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality prediction for the year 2017 with focus on lung cancer. Ann Oncol 2017; 27:1117-23.
8. Schiffman JD, Fisher PG, Gibbs P. Early detection of cancer: past, present and future. Am Soc Clin Oncol Educ Book 2015; 35:57-65.
9. Saarenheimo J, Eigeliene N, Andersen H, Tiirola M, Jekunen A. The value of liquid biopsies for guiding therapy decision in non-small cell lung cancer. Front Oncol 2019; 9:129.
10. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553:446-54.
11. Trama A, Boffi R, Contiero P, Buzzoni C, Pacifici R, Mangone L, et al. Trends in lung cancer and smoking behavior in Italy: an alarm bell for women. Tumori 2017; 103:543-50.
12. Fortunato O, Gasparini P, Boeri M, Sozzi G. Exo-miRNAs as a new tool for liquid biopsy in lung cancer. Cancers (Basel) 2019; 11:888.
13. Lung cancer screening. CDC report. (Accessed June 13, 2021, at: hhtps://www.cdc.gov.cancer.lung.)
14. Dama E, Melocchi V, Colangelo T, Cuttano R, Bianchi F. Deciphering the molecular profile of lung cancer: New strategies for early detection and prognostic stratification. J Clin Med 2019; 8:108.
15. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J. Early and locally advanced NCSLC. ESMO clinical guideline for diagnosis/treatment and follow-up. Ann Oncol 2017; 28:iv1-21.
16. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 2018; 16:370-78.
17. Herceg Z, Halinaut P. Genetic and epigenetic alteration as biomarkers for cancer detection, diagnosis and prognosis. Med Oncol 2007; 1:26-41.
18. Ansari J. The liquid biopsy in lung cancer. Genes Cancer 2016; 7:355-69.
19. Nature news comments. Liquid-biopsies success highlights power of combining basic and clinical research. Nature 2017; 544:393.
20. Wu Z, Vang Z, Daei J, Zhu Q, Chen LA. Update on liquid biopsy in clinical management of NSCLC. Oncol Target Ther 2019; 12:5097-109.
21. Hofman P. liquid biopsy for early detection of lung cancer. Curr Opin Oncol 2017; 1:73-8.
22. Santarpia M, Liguori A, D’Aveni A, Karachaliou N, Gonzalez-Cao M, Grazia Daffinà M. Liquid biopsy for lung cancer early detection. J Thorac Dis 2018; 10:s882-97.
23. Best MG, Wesselling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res 2018; 78:3407-12.
24. Du X, Zhang J, Wang J, Lin X, Ding F. Role of microRNAs in lung cancer; potential biomarkers and therapies. Curr Pharm Des 2018; 23:3997-6010.
25. Su YH. Liquid biopsy: an old concept with a new twist. Genetic testing and molecular biomedicine, 2019. Seracare. (Accessed December 6, 2021, at https://www.genengnews.com/insight/liquid-biopsy-an-old-concept-with-a-new-twist/.)
26. Ashworth T. A case of cancer in which cells similar to those in the tumor were seen in blood after death. Med J Sust 1869; 14:146-7.
27. Follain G. Hemodynamic force tune the arrest, adhesion and extravastion of circulating tumor cell. Dev Cell 2018; 45:33-52.
28. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer genetic in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
29. Prakis S, Speicher MR. Merging in liquid biopsy. BMC Med 2017;15:79.
30. COBAS. COBAS EGFR Mutation Test v2. (Accessed at, https://www.cobaCF.com.)
31. University of Texas M D Anderson Cancer Center. Liquid as effective as tissue biopsy for NSCLC. Science Daily; February 27, 2019.
32. Bayes-ginis A, Nonez J. Step-by-step towards biomarker based precision medicine in heart failure. Clin Chem 2019;65:1187-9.
33. Lim M, Kim CJ, Sunkara V, Kim MH, Cho YK. Liquid biopsy in lung cancer: clinical application of circulating biomarkers (CTCs and ctDNA). Micromachines(Basel) 2018;9:100.
34. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018; 10:1758835918794630.
35. Sittka A, Schmeck B .MicroRNAs in the lung. Adv Exp Med Biol 2013:774; 121-34.
36. Sessa R, Hata A. Role of microRNAs in lung development and pulmonary diseases. Pulm Circ 2013; 3:315-28.
37. Muller S, Janke F, Dietz S, Sültmann H. Circulating microRNAs as potential biomarkers for lung cancer. Recent Results Cancer Res.2020; 215:299-318.
38. Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med 2015; 109:803-12.
39. Cruz-Miranda GM, Hidalgo-Miranda A, Bárcenas-López DA, Núñez-Enríquez JC, Ramírez-Bello J, Mejía-Aranguré JM, et al. Long non-coding RNA and acute leukemia. Int J Mol Sci 2019; 20:735.
40. Joosse SA, Gorges TM, Pantel K. Biology, detection and clinical implication of circulating tumor cells. EMBA Mol Med 2015; 7:1-11.
41. Kim WJ, Lim JH, Hong Y, Hong SH, Bang CY, Lee JS, et al. Altered miRNAs expression in lung tissue of patients with COPD. Mol cell toxicol 2017; 13:207-12.
42. Mondejer-Perreno G, Gallajo M, Cogolludo A, Pérez-Vizcaíno F. MicroRNAs in respiratory diseases. Nucleic acid nanotheranstics 2019;2:89-131.
43. Castro D, Moreiera M, Gouveia AM. Pozza DH, De Mello RA. MicroRna in lung cancer. Oncotarget 2017; 8:81679-85.
44. Padgin T, Lavander P. MicroRNAs in lung disease. Thorax 2012; 67:182-4.
45. Mitcheli PS, Parkin RK, Keroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood–based markers for cancer detection. Proc Nat Acad Sci USA 2008; 105:10513-8.
46. Lu J, Getz G, Miska EA, Lamb J, Peck D, Sweet-Cordero A, et al. MicroRNA genes expression profiles classify human cancer. Nature 2005; 435:834-8.
47. Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western population. Cancer Med 2018; 7:4849-62.
48. Lee RC, Feinbaum RL, Ambros V. The C-elegans heterchronic gene lin-4 encode small RNAs with antisense complementarity to lin-4. Cell 1993; 75:843-54.
49. Pasquinelli AE, Reinhart BJ, Slack F, Kuroda MI, Maller B, Hayward DC, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408:86-9.
50. Bahadori M. New advances in RNAs. Arch Iran Med 2008; 11:435-43.
51. Iorio MV, Croce CM. MicroRNAs in cancer. Small molecules with huge impact. J Clin Oncol 2009; 27:5848-56.
52. Bagheri A, Khorshid HRK, Tavallaei M, Mowla SJ, Sherafatian M, Rashidi M, et al. A panel of non-coding RNA in NSCLC. J Cell Biochem 2018 (Online ahead of print).
53. Gasparri ML Cosarelli A, Bardhi E, Raad Besharat A, Savone D, Ruscito I, et al. Beyond circulating microRNAs: urinary miRNAin ovarian and breast cancer. Tumori Biol 2017; 39:1010428317695525.
54. Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y, et al. The role of micro RNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int J Mol Sci 2017; 18:2540.
55. Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, et al. Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy:a prospect study. Clin Cancer Res 2019; 25:2166-73.
56. Mizuno k, Mataki H, Seki N, Kumamoto T, Kamikawaji K, Inoue H, et al. MicroRNAs in NSCLC and idiopathic pulmonary fibrosis. J Hum Genet 2017; 62:57-65.
57. Lu J, Zhan Y, Feng J, Luo J, Fan S. MicroRNAs associated with therapy of non-small cell lung cancer. Int J Buiol Sci 2018; 14:390-7.
58. Cui S, Cheng Z, Qin W, Jiang L. Exosome as a liquid biopsy for lung cancer. Lung Cancer 2018; 116:46-54.
59. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosome. Curr Opin Cell Biol 2014; 29:116-25.
60. Christianson HC, Svensson KJ, van Kuppevelt TH, Li JP, Belting M. Cancer cell exosome depend on cell surface heparin sulfate proteoglycans for their internalization and functional activity. Proc Nat Acad Sci USA. 2013; 110:17380-85.
61. Hoshino A, Costa Siva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumor exosome integrins determine organotropic metastasis. Nature 2015; 527:329-35.
62. Sanz-Rubio D, Martin-Burriel I, Gil A, Cubero P, Forner M, Khalyfa A, et al. Stability of circulating exosomal miRNAs in healthy subjects. Sci Rep 2018;8:10306.
63. Kim JH, Kim E, Lee MY. Exosome as diagnostic biomarkers in cancer. Mol Cell Toxicol 2018; 14:113-22.
64. Izzotti A, Carozzo S, Pulliero Q, Zhabayeva D, Ravetti JL, Bersimbaev R. Extracellular microRNA in liquid biopsy: applicability in cancer diagnosis and prevention. Am J Cancer Res 2016; 6:1461-93.
65. Chen X, Jin Y, Feng Y. Evaluation of plasma extracellular vesicle MicroRN signature for lung adenocarcinoma and granuloma with Monte Carlo feature selection method. Front Genet. 2019; 10:367.
66. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Respect Clin Res 2016; 7:68-74.
67. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell carcinoma using a novel microRNA – based approach. Clin Cancer Res 2010; 16:610-9.
68. Hamamoto J, Soeijima K, Yoda S, Naoki K, Nakayama S, Satomi R, et al. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep 2013; 8:456-62.
69. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, et al. Classification of the four main types of lung cancer using amicroRNA-based diagnostic assay. J Mol Diag 2012; 14:510-7.
70. Kim J, Lim NJ, Jang SG, Lee GK. MiR-592 and miR-552 can distinguish between primary lung adenocarcinoma andcolorectal cancer metastasis in the lung. Anticancer Res 2014; 34:2297-302.
71. Zaporozhchenko IA, Morozkin ES, Skvortsova TE, Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Plasma miR-196 and miR-183 is potential biomarkers of lung cancer. PLoS One 2016;11:e65261
72. Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating microRNA as noninvasive biomarkers for early detection of NSCLC. PLoS One 2015; 10:e0215026.
73. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC,et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations,copy number,chromosomal instability, and methylation. PLoS One 2012; 7:e36530.
74. Dama E, Melocchi V, Dezei F, Pirroni S, Carletti RM, Brambilla D, et al. An aggressive subtype of stage I lung adenocarcinoma with molecular and prognostic characteristics typical of advanced lung cancer. Clin Cancer Res 2017; 23:62-72.
75. de Bruin EC, Mc Granahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability process defines lung cancer evolution. Science 2014; 346:251-6.
76. Su JL, Chem PS, Johansson G, Kuo ML. Function and regulation of let-7 family microRNAs. Microma 20212; 1:34-9.
77. Roush S, Slack FJ. The let-7 family of miRNAs. Trends cell Biol 2008; 10:505-16.
78. Zhang J, Fujimoto J, Wedge DC, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lug adenocarcinoma delineated by multiregion sequences. Science 2014; 346:256-9.
79. Xiao W, Zhong Y, Wu L, Yang D, Ye S, Zhang M. Prognostic value of microRNAs in lung cancer: A systematic review and meta-analysis. Mol Clin Oncol 2019; 10:67-77.
80. Wikipedia. OncomiR. (Accessed at, https://en.wipedia.org>wiki>oncomir.)
81. Hamond SM. RNAi, microRNA and human disease. Cancer Chemother Pharmacol 2000;58:s63-8.
82. Calin GA, Du Mitro CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequentdeletin and down-regulation of microRNA genes miR-15 and mir-16 at 13q14 in chronic lymphocytic leukemia.Pro Nat Acad USA 2002;99:15524-9.
83. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29:618-26.
84. Yang M, Shen H, Qui C, Ni Y, Wang L, Dong W, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavorable survival in NSCLC. Eur J Cancer 2013; 49:604-15.
85. Si W, Shen JN, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics 2019; 11:25.
86. Frixa T, Donzelli S, Blanding G. Oncogenic MicroRNAs; key players in malignant transformation. Cancers (Basel) 2015; 7:2466-85.
87. Zhang C, Wang H, Liu X, Hu Y, Ding L, Zhang X, et al. Oncogenic microRNA-411 promote lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene 2018; 38:1892-909.
88. Pan X, Wang ZX, Wang R. MicroRNA-21, a novel therapeutic target in human cancer. Cancer Biol Ther 2010; 12:1224-32.
89. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu Q, et al.microRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 2013; 17; 1073-80.
90. Sachdeva M, Zhu S, Mo YY. MicroRNA-21 as a novel therapeutic target in cancer. Current Cancer Therapy 2010; 6:41-50.
91. Holohan C, Van schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistant: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26.
92. Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in NSCLC, a challenge landscape. Ann Oncol 2016; 27:2004-16.
93. Vargas AJ, Harris CC. Biomarker development in the precision medicine era. Lung Cancer as a case study. Nat Rev Cancer 2016; 16:325-37.
94. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision Medicine. Cancer Res 2019; 79:2798-804.
95. Saliminezad K, Khorshid HRK, Ghaffari SH. Why have microRNA biomarkers not been translated from bench to clinic.Future Oncol 2019;15.(Published Online)
96. Wholly D. The biomarkers consortium. Nat Rev Drug Discov 2014; 13:791-2.
97. Menetski J, Austin CP, Brady LS, Eakin G, Leptak C, Meltzer A, et al. The FINH biomarkers consortium embraces the BEST. Nat Rev Drug Discov 2019;18:567-8.
| Files | ||
| Issue | Vol 59, No 5 (2021) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/acta.v59i5.6657 | |
| Keywords | ||
| Liquid biopsy Cancer detection Lung cancer microRNAs | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Bahadori M, Dabiri S, Azizi MH, Bahadori N. Emerging Role of microRNAs as Liquid Biopsy Biomarkers in Lung Cancer: A Review. Acta Med Iran. 2021;59(5):239-248.
